Patents by Inventor Ryo Itooka

Ryo Itooka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxyalkyl thiadiazole derivatives
    Patent number: 10399968
    Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: September 3, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka
  • HYDROXYALKYL THIADIAZOLE DERIVATIVES
    Publication number: 20180327399
    Abstract: Problem to be Solved There is a need for a new antibiotic having a novel mechanism of action which exhibit strong antibacterial activity not only against sensitive bacteria but also against resistant bacteria thereof, and at the same time possesses excellent solubility an a safety profile amenable to human use. Solution to the Problem As a result of intensive research, the present inventors have found that a compound represented by general formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof inhibits DNA gyrase GyrB subunit and/or topoisomerase IV ParE subunit possesses excellent solubility and a safety profile for use in humans for the treatment of bacterial infectious diseases.
    Type: Application
    Filed: September 28, 2016
    Publication date: November 15, 2018
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Manoj Kumar Khera, Tarun Mathur, Jitendra A. Sattigeri, Nobuhisa Masuda, Tsuyoshi Soneda, Yoshiko Kagoshima, Toshiyuki Konosu, Tetsuya Suzuki, Makoto Yamaoka, Ryo Itooka